Exelixis (EXEL) Change in Receivables (2013 - 2026)
Exelixis (EXEL) posted quarterly Change in Receivables of $42.0 million for Q2 2026, up 160.75% year-over-year from $16.1 million in Q2 2025, and up 284.27% quarter-over-quarter from -$22.8 million in Q1 2026.
Analysis
Exelixis (EXEL) Change in Receivables (2013 - 2026) Analysis & Trends
Exelixis' Change in Receivables history runs 14 years deep, the most recent figure standing at $42.0 million for Q2 2026.
- In Q2 2026, Change in Receivables rose 160.75% year-over-year to $42.0 million; the TTM figure through Apr 2026 stood at $47.3 million (up 15.68% YoY), while the FY2026 annual figure was $21.4 million, down 23.44% from the prior year.
- Change in Receivables for Q2 2026 stood at $42.0 million, up from -$22.8 million in the prior quarter.
- The five-year high for Change in Receivables was $156.0 million in Q2 2024, with the low at -$127.0 million in Q3 2024.
- The 5-year median for Change in Receivables is $3.2 million (2024), against an average of $2.8 million.
- The sharpest annual moves came in 2023 and 2024: Change in Receivables slumped 27370.73% in 2023, then soared 18223.93% in 2024.
- Exelixis' Change in Receivables stood at $41000.0 in 2022, then plunged by 27370.73% to -$11.2 million in 2023, then slumped by 1036.08% to -$127.0 million in 2024, then surged by 113.67% to $17.4 million in 2025, then soared by 141.97% to $42.0 million in 2026.
- Business Quant data shows EXEL's Change in Receivables at $42.0 million in Q2 2026, -$22.8 million in Q1 2026, and $17.4 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -53.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 117.58 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 31.60 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 37.16 Mn |
| 10 | Exelixis | 14.81 Bn | 13.97 Bn | 608.03 Mn | -6.73 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jul 3, 2026 | -6.73 Mn |
| Apr 3, 2026 | 42.03 Mn |
| Jan 2, 2026 | -22.81 Mn |
| Oct 3, 2025 | 17.37 Mn |
| Jul 4, 2025 | 10.72 Mn |
| Apr 4, 2025 | 16.12 Mn |
| Jan 3, 2025 | -4.24 Mn |
| Sep 27, 2024 | -127.03 Mn |
| Jun 28, 2024 | 156.05 Mn |
| Mar 29, 2024 | 3.17 Mn |
| Dec 29, 2023 | -11.18 Mn |
| Sep 29, 2023 | 15.49 Mn |
| Jun 30, 2023 | -861,000.00 |
| Mar 31, 2023 | 19.18 Mn |
| Dec 30, 2022 | 41,000.00 |
| Sep 30, 2022 | -20.20 Mn |
| Jul 1, 2022 | 45.10 Mn |
| Apr 1, 2022 | -91.79 Mn |
| Dec 31, 2021 | 102.20 Mn |
| Oct 1, 2021 | 7.81 Mn |